Connect with us

Hi, what are you looking for?

Sunday, Apr 20, 2025
Mugglehead Investment Magazine
Alternative investment news based in Vancouver, B.C.
Canadian government to grant $3M for psilocybin research studies
Canadian government to grant $3M for psilocybin research studies
Photo via Numinus

Canada

Canadian government to grant $3M for psilocybin research studies

The aim is to expand the evidence base on psilocybin-assisted psychotherapy to inform practical policies and regulations

Canada’s federal research agency will give researchers $3 million to look into the benefits of using psilocybin to treat mental health illnesses.

Last week, the Canadian Institutes of Health Research (CIHR) launched a grant application to fund psychedelic-assisted psychotherapy research for three specific mental health illnesses.

The research will support Phase 1 or 2 randomized clinical trials relevant to psilocybin use to treat substance use dependence or disorders, major depressive disorder and end-of-life psychological distress in patients with advanced-stage cancer.

The purpose is to strengthen the evidence base and expand research through new clinical trials.

Funding will be provided by the Canadian Drugs and Substances Strategy (CDSS), under the leadership of Health Canada and in partnership with the CIHR Institute of Neurosciences, Mental Health and Addiction (CIHR-INMHA).

“The current funding opportunity will expand the evidence base around psilocybin-assisted psychotherapy to inform practical policies and regulations that aim to improve the health of Canadians and people living in Canada who are experiencing psychiatric disorders,” reads the funding announcement.

Read more: Numinus to enter US psychedelics market via $26.2M Novamind acquisition

Read more: Vancouver Island University to launch Canada’s first psychedelic-assisted therapy graduate program

The total fund of $3 million will be split into three grants, where the maximum amount per grant is $500,000 per year for up to two years for a total of $1 million per grant studying a mental disorder each.

“It is strongly encouraged that people with lived and/or living experience are included in the research team to participate in study design, implementation, knowledge mobilization and/or other aspects of the research process, where appropriate,” reads the funding description.

The registration deadline will run until September 6 and the application deadline ends on October 4. Funding will start at the beginning of March 2023.

The CIHR will host webinars to support applicants with the requirements of this funding and answer questions, with the first one starting on June 9.

 

Follow Mugglehead on Twitter

Like Mugglehead on Facebook

Follow Natalia Buendia Calvillo on Twitter

natalia@mugglehead.com

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

Medical and Pharmaceutical

It will get phased in within the next 2 years

Psychedelics

"The Special Access Program is inefficient and insufficient," PsyCan's executive director said

Gold

Vancouver-based Equinox agreed to acquire Calibre in an all-stock deal to increase gold production and consolidate assets across the Americas

Gold

Collective is a gold, silver, copper, and tungsten exploration company with projects in Caldas, Colombia